SARASOTA, Fla., Sept. 3, 2021 /PRNewswire/ -- INVO
Bioscience, Inc. (NASDAQ: INVO), a medical device
company focused on commercializing the world's only in vivo Culture
System (IVC), INVOcell®, announced today that Dr. Inger Britt Carlsson will be presenting at the
Association for Fertility and Reproductive Health (AFRH) virtual
conference this year on September
23rd and 24th on the topic of
INVOcell® as an efficient, patient-centric and affordable fertility
solution for the continent of Africa.
"Across the African continent, infertility is on the rise, with
an average infertility rate of 10.1% and as high as 32% in some
countries," said Dr. Carlsson. "Infertility comes with devastating
social, cultural, emotional and economic consequences for young
couples in Africa. Unfortunately,
accessing basic assisted reproductive technology treatments can be
challenging or impossible for couples who have issues conceiving.
The INVOcell solution is a low-cost and effective fertility
treatment option that can be the answer to this burgeoning
dilemma."
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate
experience.
Steve Shum, CEO of INVO
Bioscience, commented, "Prior to the start of the pandemic, INVO
Bioscience entered into a distribution agreement in Nigeria, the most populous (~212 million)
country in Africa, with G-Systems.
We have recently completed the registration process in Nigeria as well as hosted training events with
our distributor. We believe the African continent represents
an attractive opportunity for INVOcell and look forward to
accelerating our efforts to democratize fertility across the
African continent."
About INVO Bioscience
We are a medical device company focused on creating simplified,
lower-cost treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-inger-britt-carlsson-vice-president-of-global-medical-affairs-for-invo-bioscience-to-present-at-the-11th-annual-afrh-virtual-conference-301368922.html
SOURCE INVO Bioscience, Inc.